Analysis adds to concerns about weight-loss methods and dietary protein intake

With 1 in 5 overweight Americans pang from ongoing kidney disease, Cleveland Clinic researchers analyzed a nutritive and lifestyle habits of overweight adults, anticipating that their methods enclosed diets and diet pills that might means serve kidney damage.

The investigate findings, published online this month in a International Journal of Obesity, came from an research of food choices and lifestyle habits of 10,971 overweight adults taken from a National Health and Nutrition Examination Survey (NHANES), a federally-administered comment of a altogether health and nutritive standing of Americans.

Of a overweight and portly patients with kidney illness enclosed in a survey, 50 percent reported that they had attempted to remove weight in a past year. The consult showed that, on average, portly Americans with kidney illness devour protein in amounts that are above a endorsed levels prescribed by a National Kidney Foundation for ongoing kidney illness patients.

The standard American diet any day includes approximately 1.2g of protein per kilogram of physique weight. Patients with CKD are suggested to devour 0.6g to 0.75g protein per kilogram of physique weight any day and renouned high-protein diets might call for adult to 1.9g per kilogram of physique weight.

“People who are overweight or portly are during aloft risk for ongoing kidney illness and there is a good need to conclude what a suitable lifestyle changes and weight detriment modalities are for safeguarding kidney function,” pronounced Sankar Navaneethan, M.D., a nephrologist in a Glickman Urological and Kidney Institute during Cleveland Clinic and lead author of a study. “Rather than regulating breakthrough diets or diet pills, overweight and portly people with kidney illness might adopt a weight detriment devise that incorporates a low-protein, low-calorie diet, unchanging earthy activity and tighten follow-up by their physicians.”

• Doctor focuses on weight loss
• Been hijacked by media hacker?
• ‘Best Diet’ helps health, not only weight
• Lack of nap can means weight gain
• Lack of nap can means weight gain

CouponCodes4u.com is stating that searches for gym membership discounts on their website were 67 percent lower in Jan 2012 than in Jan 2011. In contrast, searches for dieting pills on a site were adult by 51 percent in Jan 2012 compared to Jan 2011.

It has also seen a 21 percent increase in searches for cellulite creams and a delayed decrease in searches for aptness equipment.

Some thoughts on this.

First, this is information from one website, so it’s not accurately scientific. It’s probable that they’re famous for charity some-more deals on diet pills and cellulite cream than for gym memberships and practice equipment, that would askance a form of people who hunt their web site. Another banking site competence have information indicating a opposite.

Secondly, we don’t need a gym membership to exercise, so I’m going to give web searchers everywhere a advantage of a doubt and assume that many of them are operative out during home, running, cycling and blazing calories in other ways. I’m also going to assume that they’re eating healthfully.

All that being said, this is still disturbing, since it implies that a lot of people are still looking for easy, effortless, diseased ways to remove weight.

?

• Healthhound.org Talks About The Best Weight Loss Pills In A New Podcast
• Fat Burning Furnace Review Site Launches, Giving Viisitors Important …
• Healthhound.org Talks About The Best Weight Loss Pills In A New Podcast
• Healthhound.com Sets Up An Apidextra Reviews Page
• Shopping Tips On Safe Dietary Supplements Detailed In New Free Report …

Reality babes could get in trouble…

• Share
• Tweet

Whenever Khloe and Kim Kardashian wish to dump a few pounds a girls suggest a same diet supplements, though now it could finish adult with a sisters removing sued!

The Keeping Up With The Kardashian sisters could be taken to justice over a diet addition QuickTrim that they have permitted for years, since it allegedly contains too most caffeine, reports a New York Post.

Kim and Khloe frame off for a adverts in their purple bikinis and a ads have mostly been emblazoned on their blogs as good as tweeting about it when they’re behind on their diets.

Now Bursor Fisher, a law organisation who are removing prepared to record a lawsuit have said: “The active part in QuickTrim weight detriment products is a vast sip of caffeine… The FDA has dynamic that caffeine is not protected or effective for weight loss.”

The Kardashians have nonetheless to comment.

Kim infrequently likes to work out… a lot…

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• »

Tags :
Khloe Kardashian,
Kim Kardashian

You can keep adult to date with all a latest news from Entertainmentwise by following us on Twitter and liking us on Facebook.

Related Articles

• Kim Kardashian’s Diet Pills Burning 380 Calories Per Day on Sale in UK
• I’m So Excited! Snooki’s New Zantrex3 Ad Is A Flashback To Jessie Spano’s Diet …
• What First Time Diet Pills Users Need to Know
• Holly Madison’s Weight Loss Secrets!
• Snooki Weight Loss: Jersey Shore Star Flaunts New 98-Pound Body during Christmas …

JACKSONVILLE, Fla. –

This week a FDA is set to re-consider a diet tablet drug it has already rejected.

If it’s passed, it would be a initial new medication diet tablet in 13 years.

The drug is called Qnexa, though there are critical health concerns, including heart risk and birth defects.

Pharmacist Gary Roberts said, “There is a place for them. You know they can give we that initial flog or that initial start.”

Gary Roberts with Roberts pharmacy pronounced diet pills customarily work, though they’re not a healthy approach to strew neglected pounds.

Instead, many diet pills have side effects, that is because many people exclude to take them.

Marty Cawley is opposite diet pills and said, “Chemically is what we would be endangered about. The chemical multiple of a pills.”

The FDA declined to approve a drug Qnexa dual years ago, citing a risks of birth defects and cardiovascular problems. But a California formed association now wants singular capitulation of Qnexa, if it’s released from women in their childbearing years.

“Being a executive shaken complement stimulant, it can means a lot problems nutritionally. It can mistreat an unborn baby nutritionally. Also your sensitive a babies shaken system, and it could lead to problems down a road,” Roberts said.

Qnexa is a multiple of dual drugs, Phentermine, that is an ardour suppressant, and Topiramate, a drug that is used to provide seizures and migranes that can also be a mood stabilizer.

Because Qnexa isn’t accessible on a open market, some doctors have been prescribing a components, formulating an off tag brand.

Roberts along with other internal pharmacists pronounced diet pills in ubiquitous are a crutch, and mostly do some-more mistreat than good.

“The FDA should demeanour during this really closely,” Roberts said. “Some are related to being fatal.”

• FDA reiterates concerns with diet tablet as drugmaker prepares to make second …
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill

The U.S. Food and Drug Administration (FDA) continue to share their concerns over weight-loss pills that are scheming for second attempts during FDA approval.  Previously, a weight-loss drug, Qnexa, was denied approval, due to critical side effects, birth defects and heart problems.

Vivus Inc. has grown a weight-loss drug Qnexa, that was deserted by a FDA in October, 2010.  As Vivus prepares for a second try for approval, a FDA continues to share a concerns.

Qnexa is a multiple of dual existent drugs, phentermine, an ardour suppresor, and topiramate, a drug typically used for epilepsy and migraines.  Some doctors trust a member drugs are effective during handling obesity, and a dual drugs can be prescribed alone to patients.  However, a FDA is endangered about a documented side effects of Qnexa, and as a result, a FDA might need a vast new clinical hearing to reassess if Qnexa increases a risk of heart attacks.  This capitulation requirement, if implemented, would check FDA capitulation on a drug by years.

In addition, Vivus documented that when profound women take topiramate, they are during an increasing risk for infants with verbal cleft/cleft lip.

The efficiency of Qnexa is also in doubt since not everybody who took a drug mislaid poignant amounts of weight.  On average, people who took Qnexa mislaid 6.6 percent of their physique weight.  For FDA approval, a drug contingency be obliged for during slightest 5 percent of physique weight, on average. In addition, 62 percent of portly and overweight people who took Qnexa mislaid during slightest 5 percent of their physique weight. This represents about 3 times some-more weight detriment than people who took a placebo.  For FDA approval, 35 percent of people contingency remove 5 percent of their physique weight.  Qnexa has shown to be accommodate a minimal efficacy mandate for FDA approval; however, a FDA is still endangered about a reserve of a drug taken over extended durations of time.

Over a past dual years, a FDA has deserted pills from 3 drug companies, Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus.  All 3 companies are competing to have their weight-loss drug strike a marketplace initial since there has not been a new weight-loss drug in over a decade.  All 3 companies are now scheming their products for resubmission for FDA approval.

Obesity is a critical problem in a U.S., definition weight-loss drugs have an untapped population.  There is a poignant need for new weight-loss drugs to assistance people fill a opening between diet and exercise.  There are other methods to remove weight, besides diet and exercise.  Bariatric medicine has been shown to help, though a procession is concerned and invasive

The FDA is discreet about commendatory weight-loss drugs since two-thirds of Americans are overweight, representing millions of Americans who might take these weight-loss drugs.  So a FDA wants to be certain that whichever weight-loss drug is authorized is protected for a population.

• Side Effects of Diet Pill Still Concern Regulators
• New diet pills approaching to launch, only watch out for a mind frying thing…
• New diet tablet concerns FDA
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill

According to a Feburary 17 essay by a compared Press, “Federal health officials continue to voice reserve concerns about an initial diet tablet from drugmaker Vivus Inc., as a association prepares to make a second try to remonstrate experts of a drugs’ reserve subsequent week.Vivus, formed in Mountain View, Calif., is one of 3 tiny drugmakers racing to move a initial new medication weight detriment drug to marketplace in some-more than a decade. In a past dual years a Food and Drug Administration has deserted pills from all three: Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus. All 3 companies are in a routine of resubmitting their products.

The FDA had deserted a diet tablet Qnexa in Oct 2010. Vivus has resubmitted a drug with additional follow-up information, anticipating for a some-more auspicious ruling.

But in papers posted online Friday, a FDA reiterated concerns about dual reserve issues that tormented a tablet a time initial around: Potential heart problems and birth defects in women who turn profound while holding a drug.

On Wednesday a FDA will ask experts during a open assembly to import in on those issues, privately risks of split mouth defects compared with one of a mixture in Qnexa. The experts will also plead increasing blood vigour and aloft heart rates reported for patients holding a drug.

The row of doctors will take a final opinion on either a drug appears protected and effective. The group’s recommendation is not binding, and a FDA is approaching to make a final preference in April.

With U.S. plumpness rates impending 35 percent among adults, doctors and open health officials contend new weight-loss therapies are desperately needed. And even a modestly effective drug could have blockbuster potential. But nothing of a 3 medicines before a FDA represents a breakthrough in research.

Qnexa is a multiple of dual comparison drugs. The amphetamine phentermine, that is authorized for short-term weight loss, and topiramate, an anticonvulsant drug sole by Johnson Johnson as Topamax. Phentermine helps conceal appetite, while topiramate is ostensible to make patients feel some-more satiated.

Many analysts picked had Qnexa as a many earnest contender of a new intensity diet pills since of a high turn of weight detriment reported in association studies. On average, patients mislaid some-more than 10 percent of their sum physique mass.

But during Qnexa’s initial FDA row in 2010, experts fabricated by a food and drug regulator voted 10-6 to not suggest a drug’s approval. Panelists pronounced a drug was compared with a series of dangerous side effects, including suicidal thoughts, heart palpitations, memory lapses and birth defects.

On Wednesday Vivus will offer to control a follow-up investigate to guard patients for any heart problems, if Qnexa is approved. Experts will cruise either a association should be compulsory to control that investigate before FDA gives approval. The association will also offer a devise to make certain women who are expected to turn profound do not use a drug. One of a dual mixture in Qnexa, topirimate, is famous to some-more than double a risk of birth defects.

Qnexa’s other ingredient, phentermine, was one half of a dangerous fen-phen combination, a weight detriment diagnosis pushed by doctors that was never authorized by a FDA. The fast was related to heart-valve repairs and lung problems in a late 1990s, and a FDA forced drugmaker Wyeth to repel dual versions of a drug fenfluramine.

Currently there is only one medication drug on a marketplace for long-term weight loss: Roche’s Xenical, that is not widely used since of medium weight detriment results.”

Related posts:

1. New diet tablet concerns FDA
2. A new year, a new we — a final diet you’ll ever need
3. Science meets genuine life — a final diet you’ll ever need
4. Pick your ideal diet
5. Advice for diet, practice depends on gender

• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA reiterates concerns with diet tablet as drugmaker prepares to make second …
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill

WASHINGTON (AP) — Federal health officials contend they still have reserve concerns about an initial diet tablet from drugmaker Vivus Inc., as a association prepares to make a second try to remonstrate experts of a drug’s reserve subsequent week.

Vivus, formed in Mountain View, Calif., is one of 3 tiny drugmakers racing to move a initial new medication weight detriment drug to marketplace in some-more than a decade. In a past dual years a Food and Drug Administration has deserted pills from all three: Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus. All 3 companies are in a routine of resubmitting their products.

The FDA had deserted a diet tablet Qnexa in Oct 2010. Vivus has resubmitted a drug with additional follow-up information, anticipating for a some-more auspicious ruling.

But in papers posted online Friday, a FDA reiterated concerns about dual reserve issues that tormented a tablet a time initial around: Potential heart problems and birth defects in women who turn profound while holding a drug.

On Wednesday a FDA will ask experts during a open assembly to import in on those issues, privately risks of split mouth defects compared with one of a mixture in Qnexa. The experts will also plead increasing blood vigour and aloft heart rates reported for patients holding a drug.

The row of doctors will take a final opinion on either a drug appears protected and effective. The group’s recommendation is not binding, and a FDA is approaching to make a final preference in April.

With U.S. plumpness rates impending 35 percent among adults, doctors and open health officials contend new weight-loss therapies are desperately needed. And even a modestly effective drug could have blockbuster potential. But nothing of a 3 medicines before a FDA represents a breakthrough in research.

Qnexa is a multiple of dual comparison drugs. The amphetamine phentermine, that is authorized for short-term weight loss, and topiramate, an anticonvulsant drug sole by Johnson Johnson as Topamax. Phentermine helps conceal appetite, while topiramate is ostensible to make patients feel some-more satiated.

Many analysts had picked Qnexa as a many earnest contender of a new intensity diet pills since of a high turn of weight detriment reported in association studies. On average, patients mislaid some-more than 10 percent of their sum physique mass.

But during Qnexa’s initial FDA row in 2010, experts fabricated by a food and drug regulator voted 10-6 to not suggest a drug’s approval. Panelists pronounced a drug was compared with a series of dangerous side effects, including suicidal thoughts, heart palpitations, memory lapses and birth defects.

On Wednesday Vivus will offer to control a follow-up investigate to guard patients for any heart problems, if Qnexa is approved. Experts will cruise either a association should be compulsory to control that investigate before FDA gives approval. The association will also offer a devise to make certain women who are expected to turn profound do not use a drug. One of a dual mixture in Qnexa, topirimate, is famous to some-more than double a risk of birth defects.

Qnexa’s other ingredient, phentermine, was one half of a dangerous fen-phen combination, a weight detriment diagnosis pushed by doctors that was never authorized by a FDA. The fast was related to heart-valve repairs and lung problems in a late 1990s, and a FDA forced drugmaker Wyeth to repel dual versions of a drug fenfluramine.

Currently there is only one medication drug on a marketplace for long-term weight loss: Roche’s Xenical, that is not widely used since of medium weight detriment results.

• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA reiterates concerns with diet tablet as drugmaker prepares to make second …
• FDA raises reserve concerns for diet tablet Vivus

Orlistat diet pills ‘benefits transcend risks’

17^th Feb 2012 – The European medicines regulator says a advantages of weight loss pills containing orlistat, including Alli and Xenical, transcend a risk of really singular liver side effects.

The European Medicines Agency (EMA) announced a examination of a treatments in Sep 2011 after concerns about a tiny series of liver-related side effects. From Aug 2009 to Jan 2011, 4 cases of serious liver damage were reported in patients regulating Xenical, including one deadly box of liver failure and one box where a studious indispensable a liver transplant.

Xenical and Alli

Xenical is usually accessible on medication and Alli is accessible over-the-counter from pharmacies.

Orlistat belongs to a category of drugs called lipase inhibitors. Such drugs retard a viscera from interesting some of a fat in a dishes that we eat. Specifically, orlistat blocks about 25% of a fat that we consume. Fats that are not engrossed exit your physique by your stools, or bowel movements.

Benefits transcend risks

The EMA’s Committee for Medicinal Products for Human Use has resolved that a advantage of these weight detriment medicines continue to transcend their risks in a diagnosis of portly or overweight patients with a body mass index (BMI) of 28 or above.

Overall, from 1997 to Jan 2011, 21 cases of serious liver toxicity were reported where Xenical was suspicion to be a probable cause; nonetheless other factors that could have been behind a liver damage cases were present. There were 9 reports of liver disaster in people regulating Alli between May 2007 and Jan 2011, nonetheless there were other probable explanations in some cases.

The EMA says a series of cases should be seen in a context of worldwide use of Xenical and Alli by some-more than 53 million people globally and some-more than 20 million in a EU.

The product information leaflets will be updated so information about a singular liver-related side effects are a same for all orlistat-containing medicines.

• Experimental diet drug keeps weight off for 2 years
• Lap Band Side Effects: Problems for Gastric Banding Patients
• What First Time Diet Pills Users Need to Know
• Drug run wants clearer FDA manners for diet pills
• FDA reiterates concerns with diet tablet as drugmaker prepares to make second …

By MATTHEW PERRONE
AP Health Writer

WASHINGTON (AP) – Federal health officials contend they still have reserve concerns about an initial diet tablet from drugmaker Vivus Inc., as a association prepares to make a second try to remonstrate experts of a drug’s reserve subsequent week.

Vivus, formed in Mountain View, Calif., is one of 3 tiny drugmakers racing to move a initial new medication weight detriment drug to marketplace in some-more than a decade. In a past dual years a Food and Drug Administration has deserted pills from all three: Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus. All 3 companies are in a routine of resubmitting their products.

The FDA had deserted a diet tablet Qnexa in Oct 2010. Vivus has resubmitted a drug with additional follow-up information, anticipating for a some-more auspicious ruling.

But in papers posted online Friday, a FDA reiterated concerns about dual reserve issues that tormented a tablet a time initial around: Potential heart problems and birth defects in women who turn profound while holding a drug.

On Wednesday a FDA will ask experts during a open assembly to import in on those issues, privately risks of split mouth defects compared with one of a mixture in Qnexa. The experts will also plead increasing blood vigour and aloft heart rates reported for patients holding a drug.

The row of doctors will take a final opinion on either a drug appears protected and effective. The group’s recommendation is not binding, and a FDA is approaching to make a final preference in April.

With U.S. plumpness rates impending 35 percent among adults, doctors and open health officials contend new weight-loss therapies are desperately needed. And even a modestly effective drug could have blockbuster potential. But nothing of a 3 medicines before a FDA represents a breakthrough in research.

Qnexa is a multiple of dual comparison drugs. The amphetamine phentermine, that is authorized for short-term weight loss, and topiramate, an anticonvulsant drug sole by Johnson Johnson as Topamax. Phentermine helps conceal appetite, while topiramate is ostensible to make patients feel some-more satiated.

Many analysts had picked Qnexa as a many earnest contender of a new intensity diet pills since of a high turn of weight detriment reported in association studies. On average, patients mislaid some-more than 10 percent of their sum physique mass.

But during Qnexa’s initial FDA row in 2010, experts fabricated by a food and drug regulator voted 10-6 to not suggest a drug’s approval. Panelists pronounced a drug was compared with a series of dangerous side effects, including suicidal thoughts, heart palpitations, memory lapses and birth defects.

On Wednesday Vivus will offer to control a follow-up investigate to guard patients for any heart problems, if Qnexa is approved. Experts will cruise either a association should be compulsory to control that investigate before FDA gives approval. The association will also offer a devise to make certain women who are expected to turn profound do not use a drug. One of a dual mixture in Qnexa, topirimate, is famous to some-more than double a risk of birth defects.

Qnexa’s other ingredient, phentermine, was one half of a dangerous fen-phen combination, a weight detriment diagnosis pushed by doctors that was never authorized by a FDA. The fast was related to heart-valve repairs and lung problems in a late 1990s, and a FDA forced drugmaker Wyeth to repel dual versions of a drug fenfluramine.

Currently there is only one medication drug on a marketplace for long-term weight loss: Roche’s Xenical, that is not widely used since of medium weight detriment results.

Copyright 2012 The Associated Press. All rights reserved. This element might not be published, broadcast, rewritten or redistributed.

• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA reiterates concerns with diet tablet as drugmaker prepares to make second …
• FDA raises reserve concerns for diet tablet Vivus

By MATTHEW PERRONE
AP Health Writer

WASHINGTON (AP) – Federal health officials contend they still have reserve concerns about an initial diet tablet from drugmaker Vivus Inc., as a association prepares to make a second try to remonstrate experts of a drug’s reserve subsequent week.

Vivus, formed in Mountain View, Calif., is one of 3 tiny drugmakers racing to move a initial new medication weight detriment drug to marketplace in some-more than a decade. In a past dual years a Food and Drug Administration has deserted pills from all three: Arena Pharmaceuticals Inc., Orexigen Therapeutics Inc. and Vivus. All 3 companies are in a routine of resubmitting their products.

The FDA had deserted a diet tablet Qnexa in Oct 2010. Vivus has resubmitted a drug with additional follow-up information, anticipating for a some-more auspicious ruling.

But in papers posted online Friday, a FDA reiterated concerns about dual reserve issues that tormented a tablet a time initial around: Potential heart problems and birth defects in women who turn profound while holding a drug.

On Wednesday a FDA will ask experts during a open assembly to import in on those issues, privately risks of split mouth defects compared with one of a mixture in Qnexa. The experts will also plead increasing blood vigour and aloft heart rates reported for patients holding a drug.

The row of doctors will take a final opinion on either a drug appears protected and effective. The group’s recommendation is not binding, and a FDA is approaching to make a final preference in April.

With U.S. plumpness rates impending 35 percent among adults, doctors and open health officials contend new weight-loss therapies are desperately needed. And even a modestly effective drug could have blockbuster potential. But nothing of a 3 medicines before a FDA represents a breakthrough in research.

Qnexa is a multiple of dual comparison drugs. The amphetamine phentermine, that is authorized for short-term weight loss, and topiramate, an anticonvulsant drug sole by Johnson Johnson as Topamax. Phentermine helps conceal appetite, while topiramate is ostensible to make patients feel some-more satiated.

Many analysts had picked Qnexa as a many earnest contender of a new intensity diet pills since of a high turn of weight detriment reported in association studies. On average, patients mislaid some-more than 10 percent of their sum physique mass.

But during Qnexa’s initial FDA row in 2010, experts fabricated by a food and drug regulator voted 10-6 to not suggest a drug’s approval. Panelists pronounced a drug was compared with a series of dangerous side effects, including suicidal thoughts, heart palpitations, memory lapses and birth defects.

On Wednesday Vivus will offer to control a follow-up investigate to guard patients for any heart problems, if Qnexa is approved. Experts will cruise either a association should be compulsory to control that investigate before FDA gives approval. The association will also offer a devise to make certain women who are expected to turn profound do not use a drug. One of a dual mixture in Qnexa, topirimate, is famous to some-more than double a risk of birth defects.

Qnexa’s other ingredient, phentermine, was one half of a dangerous fen-phen combination, a weight detriment diagnosis pushed by doctors that was never authorized by a FDA. The fast was related to heart-valve repairs and lung problems in a late 1990s, and a FDA forced drugmaker Wyeth to repel dual versions of a drug fenfluramine.

Currently there is only one medication drug on a marketplace for long-term weight loss: Roche’s Xenical, that is not widely used since of medium weight detriment results.

(Copyright 2012 The Associated Press. All rights reserved. This element might not be published, broadcast, rewritten or redistributed.)

• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA raises reserve concerns for Vivus diet pill
• FDA reiterates concerns with diet tablet as drugmaker prepares to make second …
• FDA raises reserve concerns for diet tablet Vivus